Biogen Inc. (BIIB) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Biogen Inc. is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Blinded, Placebo-Controlled, Single- and Multiple-Ascending-Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB145 in Healthy Adult Participants. The study aims to evaluate the safety and bodily processing of BIIB145, a drug intended for multiple sclerosis, in healthy volunteers before testing in MS patients.
The study tests BIIB145, an oral drug, against a placebo. It aims to assess safety and how the drug is processed with and without food.
The study is randomized and uses a sequential intervention model with quadruple masking, meaning participants, care providers, investigators, and outcomes assessors are blinded. Its primary purpose is treatment-focused.
Key dates include the study’s start date on November 4, 2025, with the last update submitted on December 12, 2025. These dates are crucial for tracking progress and regulatory compliance.
This study could impact Biogen’s stock performance by influencing investor sentiment based on safety results. Positive outcomes may enhance Biogen’s market position in the MS treatment landscape.
The study is ongoing, with further details available on the ClinicalTrials portal.
To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.